PubMed Health⌕ Search

Biomedical subjects

T Ueda

Publications and source records attributed to T Ueda.

At least 1,333 records · Page 74Linked to original sources
PubMed1985

A multiple regression analysis of hemoglobin values and iron status in Japanese farmers.

The authors performed multiple regression analysis of hemoglobin values and the parameters related to iron dynamics. The subjects consisted of 37 farmers whose Hb, Ht, GB, SI, %-St, SFR and FEP was examined once a month for one year. 19.2% of the female farmers had anemia of which 73.8% was iron-deficiency anemia, 13.7% being latent iron deficiency. Hb, GB and FEP in males and SI, %-St, SFR, FEP in females revealed clear seasonal variations. Multiple correlation coefficient between Hb and SI, %-St, SFR, FEP as independent variables was significant in females but not in males, and the ratio of contribution (38.7%) was not very high, however, the multiple correlation coefficient was significantly high (0.622). Standard regression coefficients between Hb and SFR, FEP were significantly high (p less than 0.01). When Ht and GB were added to these 4 variables, multiple correlation coefficients (male, 0.906; female, 0.957) were remarkably high, which means serum-related variables such as Ht and GB have an undeniably important role as explanatory variables of hemoglobin levels. These standard regression coefficients showed seasonal changes.

Adult↗
PubMed1985

Synthesis and pharmacological activities of 2-alkynyl- and 2-alkenyladenine nucleosides.

A variety of 2-alkynyladenosines (2a-1) were evaluated for biological activity in antiallergic and cardiovascular tests. Compounds bearing 2-C identical to CCH(R)OH side-chain structure exhibited the most potent antiallergic activity at 0.4 mg/kg iv, in rat. These compounds, however, possessed hypotensive activity accompanied by a decrease in heart rate. Compounds substituted at the 2-position by n-pentynyl, n-hexynyl and n-octynyl showed potent hypotensive effect without showing antiallergic activity and a decrease in heart rate. Synthesis and pharmacological activities of 2-alkenyl-adenosines and 2-alkynyl-2'-deoxy- or 3'-deoxyadenosines were also described.

Adenosine↗
PubMed1985

[Clinical experience with aztreonam in the field of obstetrics and gynecology].

Aztreoman (SQ 26,776, AZT), a synthetic monobactam antibiotic, was applied clinically in the field of obstetrics and gynecology. AZT was administered by intravenous drip infusion for 6 to 8 days at a daily dose of 2 g divided in 2 times to 5 cases. Klebsiella in 1 case with puerperal endometritis, Enterococcus, Propionibacterium and Bacteroides in each 1 case with pyometra was isolated. The clinical effect of Klebsiella was excellent. Bacteroides in 1 not-examined case was good. Enterococcus and Bacteroides with pyometra was not effective. Side effects were observed in 2 cases. One case with eclampsia arised LDH and A1-P in serum and 1 case with hepatitis arised GOT and GPT in serum.

Adolescent↗
PubMed1985

[Comparative clinical study of aspoxicillin and sulbenicillin in postoperative wound infections].

A well-controlled comparative study was performed to evaluate efficacy, safety and utility of aspoxicillin (ASPC) as compared with sulbenicillin (SBPC) in the treatment of postoperative wound infections. Either 2 g of ASPC or 2 g of SBPC was administered to patients by intravenous drip infusion twice a day for 7 days. The following results were obtained: Overall clinical effectiveness rates were 82.5% (66/80) in ASPC group and 77.0% (57/74) in SBPC group, with no statistically significant difference between 2 groups. Final overall clinical improvement rates were 83.8% (67/80) in ASPC group and 81.1% (60/74) in SBPC group, with no statistically significant difference between 2 groups. As to bacteriological effectiveness, eradication rates of clinical isolates were 70.4% (38/54) in ASPC group and 74.4% (32/43) in SBPC group. There was no statistically significant difference in 2 groups. Side effects and abnormal laboratory findings were observed in 6 cases (6.7%) and 11 cases (12.4%) in ASPC group (89 cases) respectively, and 4 cases (4.4%) and 7 cases (7.8%) in SBPC group (90 cases) respectively. Especially severe adverse reactions were not observed, and there was no significant difference in the incidences of side effects and abnormal laboratory findings between 2 groups. As to overall clinical utility, utility rates were 77.5% (62/80) in ASPC group and 70.3% (52/74) in SBPC group. There was no statistically significant difference between 2 groups. These results may be indicated that ASPC is as useful as SBPC in the treatment of postoperative wound infections.

Adolescent↗
PubMed1985

[Infectious complications and infection prevention in patients with acute leukemia].

Febrile episodes in 147 patients undergoing first remission induction therapy for acute leukemia were analyzed. Febrile episodes occurred 254 times in 136 patients. The cause of fever could not be identified in 54.3% of all episodes. Antibiotic therapy was effective in 81.1% of these episodes with no cause determined. Postmortem examinations proved infections in 65.2% of patients who had fever of unknown origin before death. Sepsis and pneumonia together accounted for 53.4% of documented infections. Sepsis and pneumonia occurred most often when the patients had neutropenia (less than 500/mm3). Increase in neutrophil count and achievement of hematologic remission produced good prognosis of the infections, and the reverse was also true in some patients. Fifty percent of fetal patients died of infection. The incidence of infections, especially pneumonia and infections caused by fungi and Proteus species indicating such infections were exogenous, reduced markedly in laminar air flow rooms.

Acute Disease↗
PubMed1985

[Pharmacological and clinical studies on the long acting cefaclor (S6472)].

A study in which 375 mg of S6472 was orally given to 3 healthy adult volunteers before a meal, after a light meal, and after a usual meal in the cross-over method revealed the highest levels, both in serum and urine, in cases treated before a meal. In cases administered after a light or square meal, the serum level was less, but approximately 2 micrograms/ml over 6 hours after administration. No difference was seen in the AUC. The effective rate of S6472 when given at 750 approximately 1,500 mg/day was 74.6% in 62 patients with skin or soft tissue infectious diseases. Neither subjective or objective adverse reactions were seen in any case. Clinical laboratory testing revealed 1 case each of anemia and increased BUN, for which S6472 was not responsible.

Abscess↗
PubMed1985

[Clinical evaluation of S6472 (prolonged action preparation of cefaclor) in the treatment of skin and soft tissue infections. A double blind comparison of S6472 and cefaclor].

A double-blind comparative study of S6472 and cefaclor (CCL) was conducted to evaluate the therapeutic efficacy, safety and usefulness in the treatment of skin and soft tissue infections. Either 750 mg b.i.d. of S6472 or 750 mg t.i.d. of CCL was administered orally to patients for a period of 7 consecutive days. Of the 250 cases (123 cases of S6472 group and 127 cases of CCL group) recruited in this trial, 228 cases (114 cases of S6472 and 114 cases of CCL) were adopted by the committee members for the evaluation of therapeutic efficacy, 238 cases (118 cases of S6472 group and 120 cases of CCL group) for usefulness, and 245 cases (121 cases of S6472 group and 124 cases of CCL group) were adopted for the evaluation of side effects. The backgrounds of both patients group were almost similar. The results obtained were as follows: Overall clinical effectiveness Of the 114 patients treated with S6472, excellent clinical responses were obtained in 11 patients, good in 79, fair in 19, poor in 5 (efficacy rate 78.9%), and of the 114 patients treated with CCL, excellent were in 16, good in 78, fair in 13, poor in 7 (efficacy rate 82.5%). There was no statistically significant difference between the 2 groups. Clinical effectiveness classified by initial severity and bacteriological efficacy There was no significant difference between the 2 groups in the clinical effectiveness classified by initial severity and in the bacteriological efficacy. Side effects were noticed in 5 patients of 121 treated with S6472 (4.1%) and in 2 patients of 124 treated with CCL (1.6%), and other 13 patients developed some abnormal laboratory findings. But these undesirable reactions were mild, and developed no significant difference between the 2 groups in the incidence of side effects. There was no significant difference between the 2 groups in the usefulness of the drugs. Conclusively, 750 mg b.i.d. of S6472 is anticipative of the same clinical efficacy, safety and usefulness as compared with that of 750 mg t.i.d. of CCL in the treatment of skin and soft tissue infections.

Administration, Oral↗
PubMed1985

[A clinical trial of SM-4300 against severe infections in surgery].

SM-4300, a newly developed human immunoglobulin for intravenous use, has been evaluated clinically in combination with the antibiotics in the patients with severe bacterial, fungal or viral infections which are resistant to antibiotic therapy in the surgery. Total number of 26 patients affected with various severe infections were treated with SM-4300. Clinical effects of SM-4300 were good in 10 cases, fair in 7 cases, poor in 7 cases and unknown in 2 cases. The efficacy rate was 41.7%. Severe infections in these 26 patients consisted of 14 cases of peritonitis, 5 cases of intrathoracic infections, 4 cases of sepsis suspected and 3 cases others. Twenty-three patients had underlying diseases, in which 15 cases were patients with cancer. Clinically isolated organisms were obtained from 12 cases, of 26 strains were evaluated for bacteriological effects which were eradicated in 10 strains, decreased in 3 and persisted in 13 strains, the eradication rate being 38.5%. The subjective and objective clinical side effects were noted.

Adult↗